IP Library Patent Application 18550750
Patent Application
App. No. 18/550,750

PERFUSION CULTURE METHOD FOR CAR-T CELLS

Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US None
App. No.
18/550,750
Abstract

Provided is a perfusion culture method for CAR-T cells. The method comprises the following steps: 1) separating peripheral blood mononuclear cells from a single blood cell of a subject, and sorting the mononuclear cells to obtain T cells; 2) carrying out activation treatment on the separated T cells by using CD3/CD28 stimulation magnetic beads; 3) infecting the activated T cells by using a lentiviral vector; 4) carrying out perfusion culture on the lentivirus-infected T cells, and harvesting CAR-T cells, wherein the composition of a serum-free culture medium, which does not contain an animal-derived component, for culturing the CAR-T cells is: AIM-V+(3-9)% ISR; and the perfusion culture comprises the following stages: the first stage: when the cell density is (0.5-1.1)×10 6 cells/mL, the perfusion rate is A1, and/or the second stage: when the cell density is (1.1-2)×10 6 cells/mL, the perfusion rate is A2, and the third stage: when the cell density is >2×10 6 cells/mL, the perfusion rate is A3, and the ratio of A1 to A2 to A3 is 1:2:2.5.

Claims (27)

1 . A perfusion culture method for CAR-T cells, which comprises the following steps:

1) separating peripheral blood mononuclear cells from apheresis components of a subject, and sorting the peripheral blood mononuclear cells to obtain T cells;

2) carrying out activation treatment on the separated T cells with CD3/CD28 stimulation magnetic beads;

3) infecting the activated T cells with a lentiviral vector;

4) carrying out perfusion culture of the lentivirus-infected T cells, and harvesting CAR-T cells;

wherein a serum-free culture medium which does not contain an animal-derived component is used for culturing the CAR-T cell and the composition of the serum-free culture medium is: AIM-V+(3-9)% ISR;

the perfusion culture comprises the follow stages:

the first stage: when the cell density is 0.5-1.1×10 6 cells/mL, the perfusion rate is A 1 , and/or

the second stage: when the cell density is 1.1-2×10 6 cells/mL, the perfusion rate is A 2 , and

the third stage: when the cell density is >2×10 6 cells/mL, the perfusion rate is A 3 , wherein the ratio of A 1 to A 2 to A 3 is 1:2:2.5.

2 . The perfusion culture method for CAR-T cells according to claim 1 , wherein the composition of the serum-free culture medium which does not contain an animal-derived component is: AIM-V+(4-7)% ISR.

3 . The perfusion culture method for CAR-T cells according to claim 1 , wherein A 1 is 0.4 bioreactor volume/day, A 2 is 0.8 bioreactor volume/day, and A 3 is 1.0 bioreactor volume/day.

4 . The perfusion culture method for CAR-T cells according to claim 1 , wherein in step 4), the perfusion culture is carried out when the cell density is greater than or equal to a preset value.

5 . The perfusion culture method for CAR-T cells according to claim 4 , wherein in step 4), fed-batch culture is used before the cell density reaches the preset value, and in the process of fed-batch culture, the density of 0.3-1×10 6 cells/mL is used as the standard for feeding, the ventilation volume is 0.1-1 L/min, the rotational speed is 4-12 rpm, and the ventilation is compressed air plus 1-10% CO 2 .

6 . The perfusion culture method for CAR-T cells according to claim 5 , wherein in step 4), before the fed-batch culture, the method comprises: transferring the infected T cells to Xuri bioreactor for fed-batch culture after the number of infected T cells reaches 5-15×10 7 cells.

7 . The perfusion culture method for CAR-T cells according to claim 1 , wherein in the process of perfusion culture, the ventilation volume is 0.3-0.8 L/min, the rotational speed is 5-rpm, and the ventilation is compressed air plus 1-10% CO 2 .

8 . The perfusion culture method for CAR-T cells according to claim 1 , wherein in step 2), the step of carrying out activation treatment on the separated T cells with CD3/CD28 stimulation magnetic beads comprises: resuspending the isolated T cells to a final concentration of 1-2×10 6 cells/mL, and mixing the T cells with CD3/CD28 stimulation magnetic beads at a ratio of 0.5-10 UL of CD3/CD28 magnetic beads per 1×10 6 T cell, then culturing at 37° C.+5% CO 2 for at least 24 h.

9 . The perfusion culture method for CAR-T cells according to claim 8 , wherein the isolated T cells are resuspended with the serum-free culture medium which does not contain an animal-derived component, wherein the composition of the serum-free culture medium which does not contain an animal-derived component is: AIM-V+(3-9)% ISR.

10 . The perfusion culture method for CAR-T cells according to claim 1 , wherein in step 3), the step of infecting the activated T cells with a lentiviral vector comprises: taking out the activated and cultured T cells, adding polybrene with a final concentration of 5-10 μg/mL and mixing, then adding lentiviral vectors slowly at a multiplicity of infection of 0.25-5; mixing and then centrifuging at 1000-3000 rpm for 0.5-2.0 hours, then culturing at 37° C.+5% CO 2 for at least 24 hours.

11 . The perfusion culture method for CAR-T cells according to claim 1 , wherein the composition of the serum-free culture medium which does not contain an animal-derived component is: AIM-V+5% ISR.

12 . The perfusion culture method for CAR-T cells according to claim 4 , wherein the preset value is 0.3-1.2×10 6 cells/mL.

13 . The perfusion culture method for CAR-T cells according to claim 4 , wherein the preset value is 0.4-1.0×10 6 cells/mL.

14 . The perfusion culture method for CAR-T cells according to claim 4 , wherein the preset value is 0.5×10 6 cells/mL.

15 . The perfusion culture method for CAR-T cells according to claim 7 , wherein in the process of perfusion culture, the ventilation volume is 0.4-0.6 L/min, the rotational speed is 8-12 rpm, and the ventilation is compressed air plus (3-6) % CO 2 .

16 . The perfusion culture method for CAR-T cells according to claim 7 , wherein in the process of perfusion culture, the ventilation volume is 0.5 L/min, the rotational speed is 10 rpm, and the ventilation is compressed air plus 5% CO 2 .

17 . The perfusion culture method for CAR-T cells according to claim 8 , wherein the isolated T cells are resuspended with the serum-free culture medium which does not contain an animal-derived component, wherein the composition of the serum-free culture medium which does not contain an animal-derived component is: AIM-V+(4-7)% ISR.

18 . The perfusion culture method for CAR-T cells according to claim 8 , wherein the isolated T cells are resuspended with the serum-free culture medium which does not contain an animal-derived component, wherein the composition of the serum-free culture medium which does not contain an animal-derived component is: AIM-V+5% ISR.

Assignments (2)
CHANGE OF NAME Recorded Feb 27, 2026
From: JUVENTAS CELL THERAPY LTD.
To: JUVENTAS CO., LTD.
Reel/Frame 073921/0442 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Sep 18, 2023
From: SHI, LIN; XIE, ZHIMING; YANG, XIAOYAN; JIN, XIA; TIAN, HAOLIANG; MENG, HUAN; ZHU, HUIJUAN; HUANG, LINSHENG; LI, XINLING
To: JUVENTAS CELL THERAPY LTD.
Reel/Frame 064934/0482 →